Guangshun Yi

Antimicrobial resistance (AMR) is one of the most urgent threats to global health, projected to cause more deaths than cancer and diabetes combined by 2050.

Under the leadership of Dr. Yi, the Yi Lab is dedicated to developing innovative antimicrobial strategies to combat AMR. Our research focuses on creating next‑generation antimicrobial nanomedicines and integrating them into biomedical devices—such as catheters—to reduce hospital‑acquired infections. We also investigate bacteriophage therapy as a promising approach to treat patients infected with drug‑resistant pathogens.

Beyond AMR, we aim to enhance patient care through close collaboration with clinicians at KFSHRC. Together, we are developing advanced MRI contrast agents and flexible zinc‑ion batteries for next‑generation wearable health‑monitoring devices.

Our mission is grounded in scientific excellence, meaningful clinical impact, and a shared commitment to advancing KFSHRC as a world‑leading medical institution.

Nanomaterials synthesis.

Antimicrobial materials.

Fluorescence.

Bacteriophage therapy.

MRI contrast agent.

Zn-ion batteries.

Dr Yi is a Senior Scientist and Team Leader at the King Faisal Specialist Hospital & Research Center (KFSHRC). Before joining KFSHRC, he was a Principal Scientist with the Agency for Science, Technology and Research (A*STAR), Singapore (2009–2023). He graduated from Tsinghua University, China, with a PhD in Analytical Chemistry in 2003. He was an Associate Professor at Shandong University of Technology (2003–2004), and a Research Fellow at Singapore-MIT Alliance (2004–2006) and National University of Singapore (2006–2008). He was the Chief Technology Officer at NanoBright Technologies Pte Ltd (2008–2009). Dr. Yi’s main research areas include nanomaterials, fluorescent technology, green chemistry, and antimicrobials.